Specialty Pharmacy

Top news of the day from across the health care landscape.

A malaria protein combined with an anti-cancer drug shows promise against chemotherapy-resistant bladder cancer.

Data show communication failure accounted for 71% of serious or life-threatening errors related to medication errors.

The current outlook for biosimilar manufacturers shows significant promise.

Patients with HIV on ART may have high viral levels, immune activation, and inflammation.

Cellular mechanism may present treatment target for multiple sclerosis.

Cheryl Allen, vice president of Industry Relations at Diplomat, discusses the largest challenges currently facing independent specialty pharmacies.

Regular low-dose aspirin use associated with a lower risk of breast cancer.

Top news of the day from across the health care landscape.

Active compounds in chili peppers and cannabinoids help calm the gut.

Top articles of the week on Specialty Pharmacy Times.

Study provides visualization of different conformations of transporter in motion that may lead to more effective anticancer and antiviral drugs.

Patients who received kidney transplants from donors infected with hepatitis C virus were cured after antiviral drug therapy.

The American Health Care Act is designed to repeal and replace parts of the Affordable Care Act.

Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.

Opioid epidemic fuels hepatitis C transmission.

FDA authorizes an omalizumab (Xolair) biosimilar to commence clinical trials.

GBR 310 is a recombinant DNA-derived monoclonal antibody for the treatment of allergic asthma and chronic idiopathic urticaria.

Findings may lead to the development of a noninvasive clinical diagnostic test.

The risk of comorbid chronic obstructive pulmonary disorder in patients infected with HIV may be underestimated.

Eric Peacock, CEO of MyHealthTeams, discusses effective treatment of patients with chronic conditions.

Specialty pharmacy is the fastest growing segment thanks to drug innovation that is driving health care costs.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.

Patients in rural areas who have diabetes often have lower access to care and are more likely to be uninsured.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.

Officials with the FDA have approved the supplemental new drug application (sNDA) for BioDelivery Sciences International's buprenorphine and naloxone buccal film (Bunavail).

Exclusive, limited, and open networks each have pros and cons that must be weighed heavily.

Cutting supply of essential nutrients restrains tumors.